Tislelizumab Combined With Chemotherapy for Different Cycles of Neoadjuvant Therapy for Locally Advanced Resectable Squamous Cell Carcinoma of the Head and Neck (NeoTempo)

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2025
This study aims to explore the optimal course of neoadjuvant immunotherapy for HNSCC by comparing the efficacy and safety of 4 cycles and 2 cycles of neoadjuvant tislelizumab combined with chemotherapy.
Epistemonikos ID: 7b4c49211a8819949ec53f03ceae7dd644e43171
First added on: Aug 30, 2025